Polymers for Cardiovascular Stent Coatings

Table 1

Components and peformance of current clinically approved DES.

Type	DES	Coating	Drug	Clinical performance
Durable	Taxus Express [52, 53]	SIBS	Paclitaxel	Superior to BMS in reducing ISR and TLR
	Promus Element [54]	PBMA/PVDF-HFP	Everolimus	Comparable to Xience-V
	Endeavour [55–57]	PC	Zotarolimus	Similar safety and efficacy as Taxus with higher ST; impaired polymer integrity
	Xience-V [58]	PBMA/PVDF-HFP	Everolimus	Prevents ISR and restores vasomotion, low ST
	SymBio [59]	PLGA	Pimecrolimus/Paclitaxel	No beneficial effect compared to Taxus
Biodegradable	Endeavour Resolute [47]	BioLinx	Zotarolimus	Noninferior in safety and efficacy trials compared to durable DES
	BioMatrix [60–62]	PLA	Biolimus A9	reduced risk of CE compared to durable DES
Polymer-free	Janus Flex [63]		Tacrolimus	Higher rates of TLR and ST in comparison with Taxus
	Yukon Choice [45, 46]		Sirolimus, Trapidil	Similar to Taxus, no beneficial effects compared to durable DES

SIBS: poly(styrene-b-isobutylene-b-styrene) block copolymer, PBMA: poly(n-butyl methacrylate), PVDF-HFP: poly(vinylidene fluoride)-hexafluoropropylene, PC: phosphorylcholine polymer, PLGA: poly(lactide-co-glycolide), BioLinx: hydrophobic C10-polymer/hydrophilic C19-polymer/poly(vinyl-pyrrolidone) (PVP), and PLA: polylactide; DES: drug-eluting stent, BMS: bare metal stent, ISR: in-stent restenosis, TLR: target lesion revascularization, ST: stent thrombosis, and CE: cardiac events.